Harry Glorikian, Malorye Allison Branca
MoneyBall Medicine
Thriving in the New Data-Driven Healthcare Market
Harry Glorikian, Malorye Allison Branca
MoneyBall Medicine
Thriving in the New Data-Driven Healthcare Market
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Doctors, hospital administrators, health information technology directors, and entrepreneurs need to adapt to the changes effecting healthcare today in order to succeed. The authors map out many of the changes taking place, describe how they are impacting everyone and outline some predictions for the healthcare industry in the years to come.
Doctors, hospital administrators, health information technology directors, and entrepreneurs need to adapt to the changes effecting healthcare today in order to succeed. The authors map out many of the changes taking place, describe how they are impacting everyone and outline some predictions for the healthcare industry in the years to come.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 274
- Erscheinungstermin: 14. Juni 2022
- Englisch
- Abmessung: 254mm x 178mm x 15mm
- Gewicht: 520g
- ISBN-13: 9781032339368
- ISBN-10: 1032339365
- Artikelnr.: 64223618
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 274
- Erscheinungstermin: 14. Juni 2022
- Englisch
- Abmessung: 254mm x 178mm x 15mm
- Gewicht: 520g
- ISBN-13: 9781032339368
- ISBN-10: 1032339365
- Artikelnr.: 64223618
Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending. He currently serves as General Partner at New Ventures Funds. Before joining New Ventures Funds, he served as an Entrepreneur In Residence to GE Ventures - New Business Creation Group. He currently serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures). Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories. Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets. He is also the Author of two books: Commercializing Novel IVD's; A Comprehensive Manual for Success and MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market. Malorye Allison Branca is an award-winning medical science writer, reporting on healthcare topics for more than 20 years. With a focus on new technologies, she tracks their impact on medical progress, from drug discovery to healthcare delivery. Branca's work has been published in Nature Biotechnology, Science, Harvard Magazine, Bio-ITWorld, Nature Reviews: Drug Discovery, and Pink Sheet: Pharma Intelligence. She has also helped craft editorials that have appeared in Xconomy, the Financial Times, and The Wall Street Journal. While at Bio-ITWorld, she won the Jessie H. Neal National Business Journalism Award and the ASBPE (American Society of Business Publication Editors) Gold prize. Branca has collaborated on books, research articles, and opinion pieces with dozens of experts, including a Nobel Peace Laureate and several executives-such as the co-founder of a major medical device company, the chancellor of a medical school, a former VP of health benefits at Walmart, and the founder of a biotech investment fund. She has also produced materials for the international nonprofit groups Grameen Bank, Grameen Healthcare, and Grameen VidaSana.
Introduction: Welcome to the Age of Moneyball Medicine
Chapter 1: The $10 Trillion Healthcare Industry's Moneyball Moment
Chapter 2: Precision Medicine: Data-Driven Diagnosis and Treatment
Chapter 3: Personally Tailored Cancer Treatment
Chapter 4: Baby Testing Boom: Genomics-Based Prenatal Diagnostics
Chapter 5: New Hope for People with Rare Diseases
Chapter 6: Price and Quality Transparency: The Dawn of Medical Shopping
Chapter 7: Value-Based Care: Paying for Results
Chapter 8: Data-Driven Drug Discovery and Development
Chapter 9: The Next-Generation Health System
Chapter 10: Digital Health: Moving from Sci-Fi Fantasy to a New Healthcare
Reality
Conclusion: The Next-Generation Healthcare Landscape
Chapter 1: The $10 Trillion Healthcare Industry's Moneyball Moment
Chapter 2: Precision Medicine: Data-Driven Diagnosis and Treatment
Chapter 3: Personally Tailored Cancer Treatment
Chapter 4: Baby Testing Boom: Genomics-Based Prenatal Diagnostics
Chapter 5: New Hope for People with Rare Diseases
Chapter 6: Price and Quality Transparency: The Dawn of Medical Shopping
Chapter 7: Value-Based Care: Paying for Results
Chapter 8: Data-Driven Drug Discovery and Development
Chapter 9: The Next-Generation Health System
Chapter 10: Digital Health: Moving from Sci-Fi Fantasy to a New Healthcare
Reality
Conclusion: The Next-Generation Healthcare Landscape
Introduction: Welcome to the Age of Moneyball Medicine
Chapter 1: The $10 Trillion Healthcare Industry's Moneyball Moment
Chapter 2: Precision Medicine: Data-Driven Diagnosis and Treatment
Chapter 3: Personally Tailored Cancer Treatment
Chapter 4: Baby Testing Boom: Genomics-Based Prenatal Diagnostics
Chapter 5: New Hope for People with Rare Diseases
Chapter 6: Price and Quality Transparency: The Dawn of Medical Shopping
Chapter 7: Value-Based Care: Paying for Results
Chapter 8: Data-Driven Drug Discovery and Development
Chapter 9: The Next-Generation Health System
Chapter 10: Digital Health: Moving from Sci-Fi Fantasy to a New Healthcare
Reality
Conclusion: The Next-Generation Healthcare Landscape
Chapter 1: The $10 Trillion Healthcare Industry's Moneyball Moment
Chapter 2: Precision Medicine: Data-Driven Diagnosis and Treatment
Chapter 3: Personally Tailored Cancer Treatment
Chapter 4: Baby Testing Boom: Genomics-Based Prenatal Diagnostics
Chapter 5: New Hope for People with Rare Diseases
Chapter 6: Price and Quality Transparency: The Dawn of Medical Shopping
Chapter 7: Value-Based Care: Paying for Results
Chapter 8: Data-Driven Drug Discovery and Development
Chapter 9: The Next-Generation Health System
Chapter 10: Digital Health: Moving from Sci-Fi Fantasy to a New Healthcare
Reality
Conclusion: The Next-Generation Healthcare Landscape